Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEVOTAL: nemtabrutinib added to venetoclax-obinutuzumab for untreated TP53-altered CLL/SLL
2026-525763-40-00Phase 2Authorised
- Sponsor
- French Innovative Leukemia Organization
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemtabrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by French Innovative Leukemia Organization. Primary endpoint: Complete response/complete response with incomplete marrow recovery plus bone marrow undetectable minimal residual disease. Planned start Sep 2026; status: authorised.
02
Drugs
nemtabrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2026-525763-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525763-40-00.